February's news (to 13th at present) that affects those managing diabetes themselves or as a carer.
FREESTYLE LIBRE 2
ABBOTT RECALLS BATCH OF LIBRE 2 SENSORS
Earlier this week, Abbott announced that some FreeStyle Libre 2 sensors were potentially faulty and are being recalled. This relates to batch lot KTP005061 only.
Please check your sensors and follow the instructions on their website if you have any from the affected batch.
ABBOTT NOTIFICATION OF ISSUES WITH LIBRELINK & ANDROID APPS
Abbott have given notice to healthcare professionals of issues when Libre wearers are using a smartphone with Android 13 OS.
PWD may experience extended periods of signal loss with FreeStyle LibreLink and will not receive alarms for high or low glucose levels. You can still scan if using Libre 2, but if using FreeStyle Libre 3 on an Android phone, users may not get glucose levels or alarms. Click below to refer to Abbott's instructions of what to do.
DEXCOM ONE TRANSMITTERS TO BE LISTED ON NHS PRESCRIPTION
From 1st March 2023, transmitters for use with the Dexcom ONE CGM will be added to the NHS Drug Tariff and will be available on prescription. T1Ds using this system will need to request the transmitter from their GP, in the same way as requesting sensors.
PWD will also be able to request a Starter Kit from their GP, comprising of 1 sensor, 1 sensor applicator and 1 transmitter.
Previously, PWD had to request a Dexcom One transmitter directly from a pharmacy, without a prescription.
Following approval of Tidepool Loop by the FDA in the USA, an update from Tidepool address the question "What devices will I be able to use with Tidepool Loop when it launches?"
Unfortunately, Medtronic and Insulet, who partnered with Tidepool to support Loop development have now withdrawn from their partnership with the nonprofit organisation. However, Tidepool are understood to be working with other pump manufacturers and an announcement on partnership is expected in the near future.
DARIO PARTNERS WITH DEXCOM
DarioHealth have announced an agreement with Dexcom to integrate CGM data into their platform for multi-chronic conditions.
Through the integration of data, Dario members wearing a Dexcom CGM, will be able to receive personalised support to manage their condition and general health.
FROM SOCIAL MEDIA
METRO READER SHOCKED AT T1 INJECTING IN PUBLIC
On twitter this week, there's been a strong reaction to a comment sent in by a member of the public regarding insulin injections in public.
The Metro have been accused of promoting diabetes stigma by publishing the comment and T1s on Twitter are calling for the Metro to issue an apology or print an educational piece.
Leave a comment (all fields required)